Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein SA pseudogene 20 (RPSAP20) is a member of the RPSA gene family and is categorized as a processed pseudogene, not a protein-coding gene[7]. Pseudogenes like RPSAP20 are segments of DNA resembling normal genes but are generally regarded as nonfunctional due to accumulated mutations and lack of protein-coding potential. The canonical, functional gene in this family, RPSA, encodes the 40S ribosomal protein SA, which also serves as a laminin receptor involved in processes like protein translation, cell adhesion, cancer metastasis, and pathogen interactions[3][7]. However, RPSAP20 itself does not produce a protein product and is not considered a therapeutic target, nor does it have any known role in disease or drug interaction. Transcripts from some RPSA pseudogenes have been detected in various tissues in certain species and may have regulatory or non-coding RNA functions, but there is no evidence that RPSAP20 has a functional or pathogenic role in humans or other organisms[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein SA pseudogene 20 (RPSAP20).